Serum Institute of India gets DCGI permission to restart phase 2, 3 trials of coronavirus COVID-19 vaccine
The Serum Institute of India (SII) is all set to restart its phase two and three clinical trials for the COVID-19 vaccine after getting the nod from the Drugs Controller General of India (DCGI).
No comments:
Post a Comment